Minoxidil Oral: Scientific Profile
Publicado el · Actualizado el
Peripheral vasodilator and opener of ATP-dependent potassium channels (K+ATP). Used in research models for the study of microcirculation and the induction of the anagen phase in the hair follicle.
Oral Minoxidil is a small molecule originally classified as a potent antihypertensive agent due to its ability to relax arteriolar smooth muscle. In the field of clinical research, it has been documented that its active metabolite, minoxidil sulfate, acts as an opener of ATP-sensitive potassium channels, which results in a hyperpolarization of the cell membrane and the consequent vasodilation.
Contemporary studies focus on its role as a regulator of the follicular cycle. Unlike its topical application, oral administration in research allows the observation of a systemic response in the growth phase of the follicle (anagen) through the increase of cutaneous blood flow and the modulation of various growth factors, such as vascular endothelial growth factor (VEGF).
In preclinical models, this compound has demonstrated efficacy in reversing androgen-mediated follicular miniaturization, independently of serum testosterone levels. Its pharmacokinetics involves rapid gastrointestinal absorption with a bioavailability that allows constant plasma concentrations for the evaluation of long-term cardiovascular and dermatological side effects.
Mechanism of action
It acts primarily through its conversion into minoxidil sulfate via the sulfotransferase enzyme present in hair follicle tissue. This metabolite opens the ATP-dependent potassium channels in vascular smooth muscle cells, causing potassium efflux, membrane hyperpolarization, and the closure of voltage-activated calcium channels. In the follicle, this mechanism favors the prolongation of the anagen phase and the increase in the diameter of the hair shaft by improving perfusion in the dermal papilla.
Mechanism summary
It works as a potassium K+ATP channel opener that induces arteriolar vasodilation and stimulates biomass synthesis in the hair follicle.
Clinical Studies (8)
- Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial (Penha MA et al. · JAMA dermatology · 2024) PMID 38598226.
- Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia (Gupta AK et al. · The Journal of dermatological treatment · 2022) PMID 35920739.
- Oral minoxidil treatment for hair loss: A review of efficacy and safety (Randolph M et al. · Journal of the American Academy of Dermatology · 2021) PMID 32622136.
- A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. (Olsen EA, et al. · J Am Acad Dermatol · 2002) PMID 12196747.
- Pumpkin seed oil vs. minoxidil 5% topical foam for the treatment of female pattern hair loss: A randomized comparative trial. (Ibrahim IM, et al. · J Cosmet Dermatol · 2021) PMID 33544448.
- Evaluating the efficacy and safety of combined microneedling therapy versus topical Minoxidil in androgenetic alopecia: a systematic review and meta-analysis. (Ahmed KMA, et al. · Arch Dermatol Res · 2025) PMID 40056230.
- Efficacy and safety of oral minoxidil versus topical solution in androgenetic alopecia: a meta-analysis of randomized clinical trials. (Sobral MVS, et al. · Int J Dermatol · 2025) PMID 39425514.
- Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. (Vañó-Galván S, et al. · J Am Acad Dermatol · 2021) PMID 33639244.
Warnings
Minoxidil Oral is a research-use-only (RUO) compound; the following warnings and handling considerations apply to its laboratory use:
- Requires constant monitoring of electrolyte balance in test subjects
- Possible risk of marked hypotension in combination with other vasodilators
- Exclusively for use in preclinical research
- Presence of pheochromocytoma in research subjects
- Documented renal insufficiency
- Prior cardiac valvular dysfunction
- Known hypersensitivity to the molecule
Technical data
- CAS
- 38304-91-5
- Molecular formula
- C9H15N5O
- Molecular weight
- 209.25 Da
- Compound type
- metabolic
- Storage
- 15-30°C
- Shelf life (lyophilized)
- 36 months
- Shelf life (reconstituted)
- Not applicable (Tablets)
- Light-sensitive
- No
Frequently asked questions about Oral Minoxidil
What is Oral Minoxidil?
Peripheral vasodilator and opener of ATP-dependent potassium channels (K+ATP). Used in research models for the study of microcirculation and the induction of the anagen phase in the hair follicle.
What is the mechanism of action of Oral Minoxidil?
It works as a potassium K+ATP channel opener that induces arteriolar vasodilation and stimulates biomass synthesis in the hair follicle.
What is Oral Minoxidil researched for?
In preclinical research, Minoxidil Oral is studied mainly in: Induction of the anagen phase of the follicular cycle; Study of systemic and peripheral vasodilation; Modulation of endothelial growth factors (VEGF). Material exclusively for scientific research.
What are the chemical properties of Oral Minoxidil?
Molecular formula C9H15N5O; molecular weight 209.25 Da; CAS number 38304-91-5.
How is Minoxidil Oral stored?
Storage conditions: 15-30°C; lyophilized stability: 36 months; once reconstituted: Not applicable (Tablets).
What routes of administration are studied for Oral Minoxidil?
In research models the following are described: Oral. Use is exclusively for scientific research.